Exploratory Study Suggests Vaginal Probiotic Spray May Improve Bacterial Vaginosis Symptoms

What's new

Researchers have explored a new approach to delivering probiotics for vaginal health: a spray-type powder applied to underwear or panty liners. This method aims to overcome limitations of existing probiotic interventions, such as oral supplements and vaginal suppositories, which sometimes face challenges with consistent vaginal colonization and user adherence. The study focused on its potential to prevent and treat bacterial vaginosis (BV), a common gynecological condition characterized by an imbalance in vaginal microbiota [1].

This novel delivery system contains a blend of Lactobacillus strains, including L. plantarum, L. rhamnosus, L. paracasei, and L. crispatus. The preliminary findings suggest that this convenient application method could lead to improvements in vaginal symptoms and a reduction in the severity of BV, particularly for women already at higher risk [1].

The science behind it

The study was an exploratory, single-arm clinical trial conducted with premenopausal women aged 19–55 years. Participants were instructed to use the probiotic spray daily for four weeks. The primary outcomes assessed were changes in vaginal symptoms and Nugent scores, a microscopic grading system used to diagnose BV based on bacterial morphology. Secondary outcomes included analyzing vaginal microbiome composition using 16S rRNA gene sequencing [1].

Out of 60 enrolled participants, 45 completed the study. While overall improvement in vaginal symptoms approached statistical significance across the entire group, it was notably significant in the high-risk group (those with a baseline Nugent score of 4 or higher). In this subgroup, the mean Nugent scores significantly decreased from 6.13 to 4.63, with half of these participants showing a reduction in their score. The study also observed a significant inverse correlation between the abundance of Lactobacillus bacteria and Nugent scores, supporting the known role of these beneficial bacteria in maintaining vaginal health [1].

Regarding safety, three mild adverse events were reported, and no serious safety concerns were observed during the study period. While the overall Lactobacillus abundance and beta diversity (a measure of overall microbial community dissimilarity) did not show significant changes across the entire cohort, alpha diversity indices (measures of microbial richness and evenness) did correlate significantly with Nugent scores [1].

What it means in practice

The development of a spray-type probiotic offers a potentially more convenient and discreet option for women seeking to support their vaginal health, particularly those prone to bacterial vaginosis. The ease of applying a powder to underwear or panty liners, rather than direct vaginal insertion or daily oral supplements, could significantly improve user compliance and make long-term use more feasible [1].

For individuals with a higher baseline risk of BV, indicated by elevated Nugent scores, this probiotic spray showed promising results in reducing the severity of the condition and alleviating associated symptoms. This suggests it could be a valuable adjunctive therapy or preventative measure for managing recurrent BV. The observed safety profile, with only mild adverse events, also supports its potential for broader use [1].

However, it's important to note that this was an exploratory study. While the findings are encouraging, they do not yet establish a definitive causal effect of the intervention on the vaginal microbiome or BV outcomes. The study's design means that further research is needed to confirm these preliminary results and fully understand the clinical utility of this novel probiotic delivery system [1].

Caveats

This study was an exploratory pilot, meaning its primary goal was to investigate the feasibility and potential effects of the probiotic spray, rather than to provide definitive proof of efficacy. A significant limitation is its single-arm design, which means there was no control group for comparison. This makes it challenging to definitively attribute the observed improvements solely to the probiotic intervention, as other factors or the natural course of the condition could have played a role [1].

The sample size was relatively small, particularly for the high-risk subgroup where the most significant improvements were noted. While the Lactobacillus abundance was negatively correlated with Nugent scores, the study did not observe significant overall changes in Lactobacillus abundance or beta diversity across the entire cohort, which warrants further investigation. The study duration was also limited to four weeks, so long-term effects and sustainability of the observed benefits are unknown [1].

Finally, the study was funded by PH4 Co., Ltd., the manufacturer of the probiotic product, although the authors state the funding organization had no role in study design, data collection, analysis, or manuscript preparation. Larger, randomized, placebo-controlled trials are essential to validate these preliminary findings, establish clinical efficacy, and determine the optimal use of this spray-type probiotic for vaginal health [1].

Source: [1] https://www.nature.com/articles/s41598-026-74965-8